ArticleIn vitro cellular & developmental biology. Animal2026
miR-495-3p attenuates cerebral ischemia-reperfusion-induced neuronal inflammation and apoptosis by targeting CCL2 expression.
Article in In vitro cellular & developmental biology. Animal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to explore the function of miR-495-3p in cerebral ischemia-reperfusion injury (CI/RI) and reveal its potential molecular mechanism. In vivo and in vitro models of CI/RI were established by MACO/R and OGD/R, respectively. Neural function scores, HE staining, and TUNEL staining assessed the degree of brain tissue injury in mice. LDH assay, MTT assay, and flow cytometry evaluated neuronal toxicity, viability, and apoptosis rate. ELISA and Western blot evaluated inflammatory factors and the NF-κB pathway. Dual-luciferase reporting assay and RIP explored the targeting relationship between miR-495-3p and CCL2. miR-495-3p was abnormally low in MACO/R mouse brain tissue and OGD/R-damaged neurons, while CCL2 was highly expressed. miR-495-3p overexpression improved neuronal apoptosis and inflammation in the brain tissue of MACO/R mice. Consistent results were also obtained in in vitro experiments. Enhancing CCL2 or knocking down miR-495-3p aggravated OGD/R-induced neuronal damage. The deleterious effects of miR-495-3p knockdown were prevented by the knockdown of CCL2. miR-495-3p targeted CCL2. miR-495-3p improves CI/R-mediated neuronal apoptosis and inflammation through targeted regulation of CCL2 expression. These results provide data support for CI/RI-targeting drugs and the understanding of disease mechanisms.
Indexed as
Identifiers
41872391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.